SkinBioTherapeutics (SBTX) Stock Statistics & Valuation Metrics

SkinBioTherapeutics has a market cap or net worth of £35.26M. The enterprise value is 0.00p.

SkinBioTherapeutics has 258,779,450 shares outstanding. The number of shares has decreased by -2.65% in one year.

SkinBioTherapeutics’s return on equity (ROE) is ― and return on invested capital (ROIC) is ―.

The current PE Ratio of SkinBioTherapeutics is ―. SkinBioTherapeutics’s PEG ratio is 0.00.

In the last 12 months, SkinBioTherapeutics had revenue of 4.64M and earned -696.25K in profits. Earnings per share was 0.00.

In the last 12 months, operating cash flow was -1.30M and capital expenditures -6.30K, giving a free cash flow of -1.30M billion.

SkinBioTherapeutics pays an annual dividend of ―, resulting in a dividend yield of ―

SkinBioTherapeutics upcoming earnings date is Mar 31, 2026, TBA (Confirmed).

SkinBioTherapeutics as a current ratio of ―, with Debt / Equity ratio of 22.87%

In the past 12 months, SkinBioTherapeutics has paid -18.86K in taxes.

SkinBioTherapeutics EV to EBITDA ratio is ―, with an EV/FCF ratio of ―.

SkinBioTherapeutics has £4.78M in cash and marketable securities with £993.47K in debt, giving a net cash position of £3.79M billion.

Gross margin is 54.19%, with operating margin of ―, and net profit margin of ―.

The average price target for SkinBioTherapeutics is ―, which is 11.43% higher than the current price. The consensus rating is ―